Related Experiment Video
Updated: May 3, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
Mechanistic Rationale of Seladelpar's Clinical Efficacy through the Selective PPAR-δ Activation in Primary Biliary
Alessio Gerussi1, Matteo Fornai2
1Centre for Autoimmune Liver Diseases, Division of Gastroenterology, Fondazione IRCCS San Gerardo dei Tintori, ERN-RARE LIVER Center, Monza, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
None:
Seladelpar is a selective PPAR-δ agonist approved for the treatment of the rare cholestatic disease Primary Biliary Cholangitis, in patients who do not achieve adequate biochemical control with first-line therapy. This review outlines the characteristics of PPAR-δ, with insights into its activity across different tissues, and summarizes the pharmacology of Seladelpar, providing the background for the subsequent discussion of its clinical efficacy and safety in humans.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

